HOWL - Werewolf Therapeutics Inc

Recent News

Werewolf Therapeutics, Inc. ( HOWL ) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Commentary • 6 days, 20 hours ago • score: 0.51

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Bullish

Werewolf Therapeutics ( HOWL ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 3 months, 2 weeks ago • score: 0.34

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

GlobeNewswire • 3 months, 2 weeks ago • score: 0.09

WATERTOWN, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Werewolf Therapeutics, Inc. ( the "Company" or "Werewolf" ) ( Nasdaq: HOWL ) , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.

52W High

$4.18

52W Low

$0.60

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.65

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.57

EV/Revenue (<3 favorable)

0.67

P/S (TTM) (<3 favorable)

52.22

P/B (<3 favorable)

1.49

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

5.96%

Institutions (25–75% balanced)

49.19%

Shares Outstanding

45,729,000

Float

29,605,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-52,418,000

EPS (TTM)

-1.64

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.01%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—